Renovorx Inc (RNXT)

$0.94 +0.05 (5.22%)
Market Cap 32.74M
Revenue (ttm) 40,000.00
Net Income (ttm) -8.81M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -22,025.00%
Debt to Equity Ratio 0.00
Volume 110,700
Avg Vol 173,110
Day's Range N/A - N/A
Shares Out 36.65M
Stochastic %K 25%
Beta 1.26
Analysts Strong Sell
Price Target $5.50

Company Profile

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.

Industry: Biotechnology
Sector: Healthcare
Phone: 650 284 4433
Fax: 650 397 4433
Address:
2570 West El Camino Real, Suite 320, Mountain View, United States
Jacksonray
Jacksonray Aug. 22 at 4:14 PM
$RNXT will we see above 1$ next week?
1 · Reply
khixst
khixst Aug. 22 at 4:08 PM
Discovering the Next Wave of Biotech Innovation $MDCX, $RNXT, $JSPR, $LSB https://www.theglobeandmail.com/investing/markets/markets-news/GetNews/34326302/discovering-the-next-wave-of-biotech-innovation-mdcx-rnxt-jspr-lsb/
0 · Reply
Northern_Lightz
Northern_Lightz Aug. 22 at 3:22 PM
Strong open for $RNXT… up over 5% and holding 0.93+. Watching if volume follows through.
0 · Reply
KirkHanna
KirkHanna Aug. 22 at 7:44 AM
$RNXT https://www.reddit.com/r/10xPennyStocks/s/M20E4LZQ6k Mr. Bagai will discuss RenovoRx’s ongoing commercialization efforts and the organic revenue growth reflecting the strong clinical need and market demand for RenovoCath as a standalone targeted drug-delivery product among both new and existing customers. Mr. Bagai’s presentation will also highlight the latest developments in RenovoRx’s ongoing Phase III TIGeR-PaC clinical trial, including the Data Monitoring Committee’s (DMC) recent recommendation to continue the trial following its review of the second pre-planned interim analysis which was triggered by the 52nd death. The TIGeR-PaC trial is evaluating RenovoRx’s novel drug-device combination oncology product candidate (intra-arterial gemcitabine delivered via RenovoCath, known as IAG) for the treatment of locally advanced pancreatic cancer (LAPC).
0 · Reply
brandonscience
brandonscience Aug. 22 at 12:36 AM
$RNXT $AIM My RNXT folks, AIM’s had a rocky (and very storied) past with money troubles, management stumbles, and FDA rejections, but ampligen is a real deal biologic and its latest pancreatic cancer results with AstraZeneca’s Imfinzi finally give it a real shot at a big Phase 3 trial, which is what they have always needed. Do your DD but if youre ever getting in, now might be the time.
4 · Reply
Northern_Lightz
Northern_Lightz Aug. 21 at 6:27 PM
Big stage ahead: $RNXT presenting at H.C. Wainwright Global Conference in NYC (Sept 8–10). All eyes on next month. Will Shaun talk about accelerating adoption and repeat orders from cancer centers? or Could we hear about partnerships… or even new tumor targets beyond pancreatic cancer?
0 · Reply
Jacksonray
Jacksonray Aug. 21 at 4:49 PM
$RNXT back $0.90 and pushing +4% midday 🚀 Buyers keep stepping in on dips. looking like support is forming and momentum rebuilding.
0 · Reply
falcon_trader11
falcon_trader11 Aug. 21 at 4:22 PM
$RNXT – short interest's plunged to 0.25% (down 26% from last month), time to cover quick before it squeezes! Revenue smashed $422K in Q2 (beat estimates 28%), 13 cancer centers onboard (up from 5), Phase III trial at 95/114 enrolled with DMC green light. Low cash burn, $12.3M runway, PanTheR study starting soon, ASTRO & AIMsymposium catalysts ahead. Analysts eyeing $4-$11.50 – this biotech gem's blasting off from here!
0 · Reply
Rnxtsavior
Rnxtsavior Aug. 21 at 12:57 PM
$RNXT .70's today... reverse split looming
1 · Reply
Northern_Lightz
Northern_Lightz Aug. 21 at 12:08 PM
$RNXT
0 · Reply
Latest News on RNXT
RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 27th Annual Global Investment Conference in New York City, September 8-10, 2025

Aug 20, 2025, 8:30 AM EDT - 2 days ago

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 27th Annual Global Investment Conference in New York City, September 8-10, 2025

RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review

Aug 14, 2025, 4:05 PM EDT - 8 days ago

RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review

RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire

Aug 6, 2025, 8:30 AM EDT - 16 days ago

RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire

RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors

Jul 28, 2025, 8:30 AM EDT - 25 days ago

RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors

RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET

Jul 14, 2025, 8:30 AM EDT - 5 weeks ago

RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET

RenovoRx, Inc. (RNXT) Q1 2025 Earnings Conference Call Transcript

May 15, 2025, 9:07 PM EDT - 3 months ago

RenovoRx, Inc. (RNXT) Q1 2025 Earnings Conference Call Transcript

RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights

May 15, 2025, 4:05 PM EDT - 3 months ago

RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights

RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st

May 14, 2025, 8:30 AM EDT - 3 months ago

RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st

U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform

May 6, 2025, 8:30 AM EDT - 3 months ago

U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform

RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET

May 1, 2025, 8:30 AM EDT - 4 months ago

RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET

Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx's Ongoing Phase III TIGeR-PaC Clinical Trial

Apr 29, 2025, 8:30 AM EDT - 4 months ago

Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx's Ongoing Phase III TIGeR-PaC Clinical Trial

RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community

Apr 16, 2025, 8:30 AM EDT - 4 months ago

RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community

RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th

Apr 4, 2025, 8:30 AM EDT - 5 months ago

RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th

RenovoRx Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

Apr 1, 2025, 8:30 AM EDT - 5 months ago

RenovoRx Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting

Mar 28, 2025, 8:00 AM EDT - 5 months ago

RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting

RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting

Mar 26, 2025, 8:00 AM EDT - 5 months ago

RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting

RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET

Mar 20, 2025, 8:00 AM EDT - 5 months ago

RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET

RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025

Mar 19, 2025, 8:00 AM EDT - 5 months ago

RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025

RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders

Feb 26, 2025, 8:00 AM EST - 6 months ago

RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders

RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery

Feb 13, 2025, 8:00 AM EST - 6 months ago

RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery

RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock

Feb 11, 2025, 7:00 AM EST - 6 months ago

RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock

RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock

Feb 6, 2025, 8:49 PM EST - 7 months ago

RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock

RenovoRx Announces Proposed Public Offering

Feb 6, 2025, 4:05 PM EST - 7 months ago

RenovoRx Announces Proposed Public Offering

RenovoRx: From Clinical Promise To Commercial Reality And Trading At A Significant Discount

Feb 5, 2025, 2:14 AM EST - 7 months ago

RenovoRx: From Clinical Promise To Commercial Reality And Trading At A Significant Discount

RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025

Jan 27, 2025, 8:00 AM EST - 7 months ago

RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025

RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025

Jan 8, 2025, 8:00 AM EST - 8 months ago

RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025

RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform

Dec 30, 2024, 8:00 AM EST - 8 months ago

RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform

Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx's Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

Nov 20, 2024, 8:45 AM EST - 9 months ago

Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx's Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights

Nov 14, 2024, 8:00 AM EST - 10 months ago

RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights

RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians

Sep 25, 2024, 8:30 AM EDT - 11 months ago

RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians

RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer

Sep 19, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 26th Annual Global Investment Conference on September 9, 2024 in New York

Aug 27, 2024, 8:30 AM EDT - 1 year ago

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 26th Annual Global Investment Conference on September 9, 2024 in New York

RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

Aug 14, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist®

Jul 8, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist®

University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx's Pivotal Phase III TIGeR-PaC Clinical Trial

Jun 26, 2024, 8:30 AM EDT - 1 year ago

University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx's Pivotal Phase III TIGeR-PaC Clinical Trial

RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships

Jun 10, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships

RenovoRx CEO Issues Update Letter to Shareholders

May 30, 2024, 8:30 AM EDT - 1 year ago

RenovoRx CEO Issues Update Letter to Shareholders

Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx's TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment Delivery

May 21, 2024, 9:00 AM EDT - 1 year ago

Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx's TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment Delivery

RenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024

May 14, 2024, 9:00 AM EDT - 1 year ago

RenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024

RenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024

May 2, 2024, 9:00 AM EDT - 1 year ago

RenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024

RenovoRx Regains Compliance with Nasdaq Stockholders' Equity Requirement

Apr 18, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Regains Compliance with Nasdaq Stockholders' Equity Requirement

RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting

Apr 16, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting

RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026

Apr 15, 2024, 8:00 AM EDT - 1 year ago

RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026

RenovoRx Announces $11.1 Million at Market Private Placement

Apr 8, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Announces $11.1 Million at Market Private Placement

RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024

Apr 5, 2024, 8:30 AM EDT - 1 year ago

RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024

RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024

Mar 12, 2024, 9:00 AM EDT - 1 year ago

RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024

RenovoRx Highlights Key Leadership Promotions

Mar 8, 2024, 4:05 PM EST - 1 year ago

RenovoRx Highlights Key Leadership Promotions

RenovoRx CEO Issues Letter to Shareholders

Feb 6, 2024, 8:30 AM EST - 1 year ago

RenovoRx CEO Issues Letter to Shareholders

RenovoRx Closes $6.1 Million Private Placement

Jan 29, 2024, 8:30 AM EST - 1 year ago

RenovoRx Closes $6.1 Million Private Placement

RenovoRx Engages Oklahoma University (OU) Health as First Clinical Site in Preparation for the Pivotal Phase III CouGar Clinical Trial in Bile Duct Cancer

Dec 21, 2023, 8:30 AM EST - 1 year ago

RenovoRx Engages Oklahoma University (OU) Health as First Clinical Site in Preparation for the Pivotal Phase III CouGar Clinical Trial in Bile Duct Cancer

Jacksonray
Jacksonray Aug. 22 at 4:14 PM
$RNXT will we see above 1$ next week?
1 · Reply
khixst
khixst Aug. 22 at 4:08 PM
Discovering the Next Wave of Biotech Innovation $MDCX, $RNXT, $JSPR, $LSB https://www.theglobeandmail.com/investing/markets/markets-news/GetNews/34326302/discovering-the-next-wave-of-biotech-innovation-mdcx-rnxt-jspr-lsb/
0 · Reply
Northern_Lightz
Northern_Lightz Aug. 22 at 3:22 PM
Strong open for $RNXT… up over 5% and holding 0.93+. Watching if volume follows through.
0 · Reply
KirkHanna
KirkHanna Aug. 22 at 7:44 AM
$RNXT https://www.reddit.com/r/10xPennyStocks/s/M20E4LZQ6k Mr. Bagai will discuss RenovoRx’s ongoing commercialization efforts and the organic revenue growth reflecting the strong clinical need and market demand for RenovoCath as a standalone targeted drug-delivery product among both new and existing customers. Mr. Bagai’s presentation will also highlight the latest developments in RenovoRx’s ongoing Phase III TIGeR-PaC clinical trial, including the Data Monitoring Committee’s (DMC) recent recommendation to continue the trial following its review of the second pre-planned interim analysis which was triggered by the 52nd death. The TIGeR-PaC trial is evaluating RenovoRx’s novel drug-device combination oncology product candidate (intra-arterial gemcitabine delivered via RenovoCath, known as IAG) for the treatment of locally advanced pancreatic cancer (LAPC).
0 · Reply
brandonscience
brandonscience Aug. 22 at 12:36 AM
$RNXT $AIM My RNXT folks, AIM’s had a rocky (and very storied) past with money troubles, management stumbles, and FDA rejections, but ampligen is a real deal biologic and its latest pancreatic cancer results with AstraZeneca’s Imfinzi finally give it a real shot at a big Phase 3 trial, which is what they have always needed. Do your DD but if youre ever getting in, now might be the time.
4 · Reply
Northern_Lightz
Northern_Lightz Aug. 21 at 6:27 PM
Big stage ahead: $RNXT presenting at H.C. Wainwright Global Conference in NYC (Sept 8–10). All eyes on next month. Will Shaun talk about accelerating adoption and repeat orders from cancer centers? or Could we hear about partnerships… or even new tumor targets beyond pancreatic cancer?
0 · Reply
Jacksonray
Jacksonray Aug. 21 at 4:49 PM
$RNXT back $0.90 and pushing +4% midday 🚀 Buyers keep stepping in on dips. looking like support is forming and momentum rebuilding.
0 · Reply
falcon_trader11
falcon_trader11 Aug. 21 at 4:22 PM
$RNXT – short interest's plunged to 0.25% (down 26% from last month), time to cover quick before it squeezes! Revenue smashed $422K in Q2 (beat estimates 28%), 13 cancer centers onboard (up from 5), Phase III trial at 95/114 enrolled with DMC green light. Low cash burn, $12.3M runway, PanTheR study starting soon, ASTRO & AIMsymposium catalysts ahead. Analysts eyeing $4-$11.50 – this biotech gem's blasting off from here!
0 · Reply
Rnxtsavior
Rnxtsavior Aug. 21 at 12:57 PM
$RNXT .70's today... reverse split looming
1 · Reply
Northern_Lightz
Northern_Lightz Aug. 21 at 12:08 PM
$RNXT
0 · Reply
Purple_Tip_Capital
Purple_Tip_Capital Aug. 21 at 1:22 AM
$RNXT took a niggle today to try and catch some of that gap fill
1 · Reply
Rnxtsavior
Rnxtsavior Aug. 20 at 1:48 PM
$RNXT 10,000 BLOCK SELLS NON STOP...
0 · Reply
Rnxtsavior
Rnxtsavior Aug. 20 at 1:47 PM
$RNXT HOLY SMOKES SHEENY MAN... PUTS OUT ANOTHER DUMB PRESENTATION RELEASE THEN DUMPS QUARTER MILLION SHARES ON YOU... ALL HEADED TO THE REVERSE SPLIT ZONE... MOST LIKELY .50'S
1 · Reply
Purple_Tip_Capital
Purple_Tip_Capital Aug. 20 at 1:41 PM
$RNXT not even shorted that much. People just plain selling out of their positions.
0 · Reply
falcon_trader11
falcon_trader11 Aug. 20 at 1:29 PM
$RNXT
0 · Reply
outlawinvestor1
outlawinvestor1 Aug. 20 at 1:24 PM
$RNXT https://ir.renovorx.com/news-events/press-releases/detail/131/renovorx-ceo-shaun-bagai-to-present-at-h-c-wainwrights
0 · Reply
Mehle
Mehle Aug. 20 at 5:01 AM
$RNXT I'll hope it will fly but for me there are some confusing points. Some of the patients are discontinue the treatment. 1 patient got a perfusion of his artery. They recruit 4 patients between q1 and q2 data but they need 114 and have already 95. If they do that in the same speed then we will finisch recruiting in mid 2026.
2 · Reply
falcon_trader11
falcon_trader11 Aug. 20 at 1:58 AM
$RNXT dipped after Q2 earnings due to a $2.9M loss, but don't miss the big wins! RenovoCath sales hit $422K, beating estimates by 28%. Now in 13 top cancer centers, up from 5, with repeat orders. Phase III trial got a green light, targeting a $1B+ market by early 2026. With $12.3M cash, a new sales pro, and TAMP cutting chemo side effects 65%, analysts see $4-$11.50 targets. PanTheR study starts by Sep end, plus ASTRO Sep 27-Oct 1 & AIMsymposium Nov 17. Missed $LLY at $705, $VRTX at $390, or $REGN at $572? $RNXT could be your next oncology star! $RNXT $LLY $VRTX $REGN
1 · Reply
Purple_Tip_Capital
Purple_Tip_Capital Aug. 19 at 8:46 PM
$RNXT extremely bullish sentiment after a .40 cent drop. Give me a break lmao
0 · Reply
Northern_Lightz
Northern_Lightz Aug. 19 at 5:16 PM
$RNXT’s Phase III TIGeR-PaC enrollment is on track to complete in 2025. With a ~$35M cap, the readout could be a big swing. 🎯
1 · Reply
khixst
khixst Aug. 19 at 3:37 PM
$RNXT From 5 centers in Q1 to 13 by Q2 is a solid jump. With 4 already treating and re-ordering, how soon do the others start adding to revenue?
0 · Reply
falcon_trader11
falcon_trader11 Aug. 19 at 2:29 AM
$RNXT Excited by RNXT’s Phase III momentum and RenovoCath adoption. Kin to what’s heating up in $IMRX orphan-drug space or $CERO immunotherapy buzz could be worth keeping them both on the radar too.
1 · Reply